Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pierre Fabre
The CEO of South Korea's SK Biopharmaceuticals talks about commercialization plans, strategy for epilepsy drug cenobamate and other pipeline assets and planned IPO.
Cardiology device firms relied primarily on in-house lobbyists but also recruited external groups to sway lawmakers to adopt favorable positions on reimbursement, COVID-19, international trade and other issues from January-March 2020, says this Medtech Insight analysis.
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
- Pharmacy Services, PBMs
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Pierre Fabre Medicament S.A.